Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014 Dec 18. pii: S1083-8791(14)01378-0. doi: 10.1016/j.bbmt.2014.12.001. pmc: PMC4329079. mid: NIHMS650779
    National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.
    Jagasia MH1,  Greinix HT2,  Arora M3,  Williams KM4,  Wolff D5,  Cowen EW6,  Palmer J7,  Weisdorf D8,  Treister NS9,  Cheng GS10,  Kerr H11,  Stratton P12,  Duarte RF13,  McDonald GB14,  Inamoto Y15,  Vigorito A16,  Arai S17,  Datiles MB18,  Jacobsohn D19,  Heller T20,  Kitko CL21,  Mitchell SA22,  Martin PJ23,  Shulman H24,  Wu RS25,  Cutler CS26,  Vogelsang GB27,  Lee SJ28,  Pavletic SZ29,  Flowers ME30
    Author information
    1Department of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
    2Department of Internal Medicine, Medical University of Vienna, Vienna, Austria.
    3Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
    4Center for Cancer Research National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Department of Blood and Marrow Transplantation, Children's National Health System, Washington, District of Columbia.
    5Department of Internal Medicine, University of Regensburg, Regensburg, Germany.
    6Center for Cancer Research National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
    7Department of Hematology Oncology/Blood and Marrow Transplant, Mayo Clinic Arizona, Phoenix, Arizona.
    8Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
    9Department of Surgery, Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, Massachusetts.
    10Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
    11Hematology Department, BC Cancer Agency, Vancouver, British Columbia, Canada.
    12Pediatric and Reproductive Endocrinology Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD.
    13Department of Hematology, Institut Catala d'Oncologia, Barcelona, Spain.
    14Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
    15Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
    16Hematology and Hemotherapy Center, Hemocentro Unicamp, Campinas, Sao Paulo, Brazil.
    17Department of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California.
    18The Eye Clinic, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
    19Department of Blood and Marrow Transplantation, Children's National Health System, Washington, District of Columbia.
    20Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, Maryland.
    21Blood and Marrow Transplant Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.
    22Department of Applied Research Cancer Control and Population Sciences, National Institutes of Health, Bethesda, Maryland.
    23Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
    24Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
    25Cancer Therapy Evaluation Program, National Institutes of Health, Bethesda, Maryland.
    26Division of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
    27Oncology Department, Johns Hopkins University School of Medicine, Baltimore, Maryland.
    28Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
    29Center for Cancer Research National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
    30Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address: mflowers@fredhutch.org.
    Abstract

    The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity of chronic graft-versus-host disease (GVHD). The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence. Revisions have been made to address areas of controversy or confusion, such as the overlap chronic GVHD subcategory and the distinction between active disease and past tissue damage. Diagnostic criteria for involvement of mouth, eyes, genitalia, and lungs have been revised. Categories of chronic GVHD should be defined in ways that indicate prognosis, guide treatment, and define eligibility for clinical trials. Revisions have been made to focus attention on the causes of organ-specific abnormalities. Attribution of organ-specific abnormalities to chronic GVHD has been addressed. This paradigm shift provides greater specificity and more accurately measures the global burden of disease attributed to GVHD, and it will facilitate biomarker association studies.


    Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

    KEYWORDS: Chronic graft-versus-host disease, Diagnosis, National Institutes of Health, Staging

    Publikations ID: 25529383
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt